CD274 and cervical carcinoma: In the United States, pembrolizumab, an antibody against 1 PD-1, is approved for advanced endometrial cancers with high levels of microsatellite instability (MSI-high) and for recurrent or progressive metastatic cervical cancer positive for programmed death-ligand 1 (PD-L1).